Mr Mrs Miss Ms Dr Other

Dr
David
Selby

Patent Director

Leeds Office Manchester Office

Chemistry

Telephone. +44(0) 113 233 0100
Mobile. +44(0) 758 599 7412
Email. [email protected]

Experience

David's practice is predominantly in the areas of chemical and biomedical research tools, including analytical instrumentation, and pharmaceuticals. David's experience in these areas includes GB and European patent prosecution, drafting and international portfolio management for large corporations and universities. David also has significant experience in oppositions and appeals before the EPO. Other subject matter that falls within David's practice includes medical devices, nanotechnology and advanced materials.

David has a degree in Chemistry and a doctorate in Chemistry, as well as a law degree from the University of New South Wales. His research experience included the construction of a novel mass spectrometer, and the application of mass spectrometry to proteomics and analysis of post-translation modification of proteins. His research experience thus covers development of instrumentation and methods of chemical analysis, through to characterisation of biological materials.

David qualified as a solicitor in Sydney, Australia, where he worked in IP litigation and has also qualified as a solicitor in England and Wales. David's practice draws on this combination of scientific and legal experience, with his understanding of enforcement and opposition informing his patent drafting and prosecution, and assisting David in providing commercially focused advice in all areas of his practice.

Qualifications

Patent Attorney

Chartered (UK)
Europe


BSC

BSc in Chemistry with Hons 1

LLB

Bachelors of laws, UNSW

PHD

Chemistry

Related News

New Blog Series: IP Ingredients, Part 1: Can you patent a recipe?

A patent is a legal right that enables the patent holder to prevent others from making and using their invention in the country where the patent is granted.  To many …

Read article

UPC and Forum Shopping – Rule 17.3

Order of the classifications listed on the front of a patent and why it matters? On 1 June 2023, ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE lodged a statement of revocation of …

Read article
Event - 16th November 2023

Webinar in cooperation with the BVIZ: Licensing and Technology Transfer

HGF is pleased to invite you to our upcoming German-language webinar in cooperation with the BVIZ on “In- and Out-licensing of Technologies” on 16th of November 2023. The webinar will …

Event details

Investing in Patents for Space Tech: Safeguarding Innovations in the Space Sector

The advent of commercial launch capabilities has opened up space as a unique frontier for innovation. However, in space, any acts of patent infringement almost always go unseen. Thus, it’s …

Read article

End of EPO "10 day rule" from 1 November 2023 – 4 weeks to go

Any communications sent from the EPO on or after 1 November 2023 will no longer have the “ten day rule” applied to them.   This means that communications are deemed to …

Read article
Event - 21st, 28th November 2023

Dresden & Salzburg Seminar: Licensing and Technology Transfer

HGF is pleased to invite you to our upcoming German-language seminar on “In- and Out-licensing of Technologies” in Salzburg and Dresden. The seminar will offer you the opportunity to gain …

Event details
Event - 26th September 2023

Bioforward OBN Conference 2023

Bioforward, OBN’s ‘Roadmap for Growth’ Life Sciences event is set to take place at The King’s Centre in Oxford on Tuesday 26th September 2023. This event is designed to provide the support, skills, know-how …

Event details

AI-Powered Personalised Medicine

The integration of artificial intelligence (AI) into healthcare has ushered in a new era of personalised medicine, promising more effective and tailored treatments for patients. Traditional medical approaches often adopt …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.